✅ Product Benefits

• Dual‑mechanism control: Linagliptin (a DPP‑4 inhibitor) enhances incretin hormone levels that boost insulin release and suppress glucagon, while Metformin (a biguanide) reduces liver glucose production, slows intestinal absorption, and improves insulin sensitivity 

• Better glycaemic management: Together they target both fasting and post-prandial glucose levels, assisting comprehensive blood sugar control and reducing risk of complications like cardiovascular disease, neuropathy, and nephropathy 

• Convenient fixed‑dose: Combines two medications into a single tablet taken twice daily with meals for ease of compliance and steady dosing 

• Lower hypoglycaemia risk: Metformin does not generally cause hypoglycaemia, and linagliptin provides glucose-dependent insulin release, reducing risks, particularly when not combined with sulfonylureas 

• Well tolerated when started slowly: Common side effects—such as diarrhea, nausea, headache, or nasopharyngitis—are typically mild and resolve as your body adjusts; starting at lower doses and titrating helps minimize GI upset .

• Supports long‑term health: Using Linatin M with healthy diet and exercise helps maintain normal life and protect against serious diabetes-related complications when taken consistently .

ℹ️ Notes & Precautions

• Always take with meals to reduce stomach upset and risk of hypoglycaemia .

• Suitable as an adjunct to diet and exercise for adult patients with type 2 diabetes when both components are appropriate .

• Not recommended in patients with renal impairment, metabolic acidosis (including diabetic ketoacidosis), or known hypersensitivity to either component .

• Drug interactions may occur with P-gp or CYP3A4 inducers (e.g. rifampin) and certain cationic agents (e.g. digoxin, cimetidine), requiring careful monitoring or alternative treatments .

• Rare but serious risk of lactic acidosis—seek prompt medical attention if you experience symptoms such as rapid breathing, persistent nausea, vomiting, or abdominal discomfort .